Shanghai RAAS Blood Products Co Ltd Class A (002252) - Total Liabilities
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) has total liabilities worth CN¥5.44 Billion CNY (≈ $795.58 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Shanghai RAAS Blood Products Co Ltd Clas to assess how effectively this company generates cash.
Shanghai RAAS Blood Products Co Ltd Class A - Total Liabilities Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Shanghai RAAS Blood Products Co Ltd Clas's assets to evaluate the company's liquid asset resilience ratio.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Shanghai RAAS Blood Products Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mango Excellent Media Co Ltd
SHE:300413
|
China | CN¥9.74 Billion |
|
Promotora y Operadora de Infraestructura S. A. B. de C. V
MX:PINFRA
|
Mexico | MX$16.70 Billion |
|
Hangzhou Tigermed Consulting
SHE:300347
|
China | CN¥4.10 Billion |
|
GalaxyCore Inc
SHG:688728
|
China | CN¥-7.82 Billion |
|
Porsche Automobil Holding SE
F:PAHA
|
Germany | €7.12 Billion |
|
Ming Yang Smart Energy Group Ltd
SHG:601615
|
China | CN¥63.91 Billion |
|
OrangePL
WAR:OPL
|
Poland | zł13.78 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai RAAS Blood Products Co Ltd Clas market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai RAAS Blood Products Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai RAAS Blood Products Co Ltd Class A (2005–2024)
The table below shows the annual total liabilities of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.69 Billion ≈ $247.37 Million |
-25.81% |
| 2023-12-31 | CN¥2.28 Billion ≈ $333.44 Million |
+38.55% |
| 2022-12-31 | CN¥1.64 Billion ≈ $240.66 Million |
+23.43% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
+266.31% |
| 2020-12-31 | CN¥363.74 Million ≈ $53.23 Million |
+0.49% |
| 2019-12-31 | CN¥361.95 Million ≈ $52.96 Million |
-26.91% |
| 2018-12-31 | CN¥495.18 Million ≈ $72.46 Million |
-74.93% |
| 2017-12-31 | CN¥1.98 Billion ≈ $289.04 Million |
+32.10% |
| 2016-12-31 | CN¥1.50 Billion ≈ $218.81 Million |
+77.24% |
| 2015-12-31 | CN¥843.64 Million ≈ $123.45 Million |
+11.72% |
| 2014-12-31 | CN¥755.16 Million ≈ $110.50 Million |
+59.53% |
| 2013-12-31 | CN¥473.37 Million ≈ $69.27 Million |
+150.74% |
| 2012-12-31 | CN¥188.79 Million ≈ $27.63 Million |
+129.51% |
| 2011-12-31 | CN¥82.26 Million ≈ $12.04 Million |
-17.01% |
| 2010-12-31 | CN¥99.12 Million ≈ $14.50 Million |
+60.16% |
| 2009-12-31 | CN¥61.88 Million ≈ $9.06 Million |
-19.03% |
| 2008-12-31 | CN¥76.42 Million ≈ $11.18 Million |
-44.02% |
| 2007-12-31 | CN¥136.53 Million ≈ $19.98 Million |
-18.92% |
| 2006-12-31 | CN¥168.39 Million ≈ $24.64 Million |
+65.20% |
| 2005-12-31 | CN¥101.93 Million ≈ $14.92 Million |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more